(Q37117865)

18 August 2017

1 reference

title

Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections (English)

1 reference

18 August 2017

gram-positive bacteria

0 references

2

Michael J Rybak

1 reference

18 August 2017

Steven N Leonard

1

1 reference

PubMed ID

18363530

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

28

1 reference

18 August 2017

4

1 reference

18 August 2017

458-468

1 reference

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

18 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains in the presence of human albumin or serum and in an in vitro kinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Telavancin: in vitro activity against staphylococci in a biofilm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

In vitro activity of TD-6424 against Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Vancomycin resistance in gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Tissue penetration of telavancin after intravenous administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.4.458

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.4.458

1 reference

18 August 2017

1 reference

PubMed ID

18363530